Genoxus Publishes New White Paper Showcasing a Systematic Approach to Genomic Variant Interpretation

New publication highlights how Genoxus Variant Analysis™ integrates AI-assisted annotation, genetic evidence mapping, and variant prioritization to help researchers uncover potentially meaningful insights from whole-exome sequencing data.

SAN DIEGO, CA. — November 2, 2026 — Genoxus Labs today announced the publication of its new white paper, “From Genetic Variation to Disease Hypotheses: A Systematic Approach to Genomic Interpretation [PDF],” introducing the technical methodology, capabilities, and real-world applications of Genoxus Variant Analysis™ (GVA) version 1.0.

As whole-exome sequencing (WES) generates increasingly large volumes of genetic data, translating that information into meaningful findings remains a significant challenge for sequencing companies, research laboratories, and genetics professionals. Genoxus addresses this challenge with an integrated analysis approach designed to go beyond traditional gene-panel analysis and systematically assess genetic variants across submitted WES datasets.

Genoxus Variant Analysis™ combines AI-assisted variant annotation, curated genetic databases, disease and trait association mapping, and evidence-informed prioritization into a unified workflow. The resulting analysis organizes findings into three distinct categories:

• Primary Findings: Variants potentially associated with reported medical conditions.
• Pathogenic Findings: Variants classified as pathogenic or likely pathogenic.
• Variants of Uncertain Significance (VUS): Findings that may warrant additional investigation.

Each analysis includes a structured report and a supplementary Excel file containing detailed variant information to support further review, research, and downstream analysis.

“Generating genomic data is only the beginning. The real challenge is understanding what that data may reveal and connecting genetic findings with meaningful biological and disease associations,” said Jingqi Duan, Ph.D., CEO and Founder of Genoxus. “With Genoxus Variant Analysis™, our goal is to bring together AI-assisted annotation, established genetic evidence, and systematic prioritization to help researchers and genetics professionals explore findings that might otherwise be overlooked. We believe this approach can create new opportunities for collaboration and help organizations extract greater value from their sequencing data.”

Demonstrating the Approach Through Real-World Case Studies

The white paper presents three case studies illustrating how GVA1.0 organizes and prioritizes genetic findings across different medical histories and research scenarios.

The examples include pediatric cases involving developmental delays, neurological complications, and nystagmus, as well as an adult case involving multiple medical conditions and a family history of cancer.

Together, these examples demonstrate how the platform connects genetic variants with documented disease and trait associations, distinguishes established classifications from uncertain findings, and identifies areas that may warrant further professional investigation.

Designed to Complement Existing Genomics Workflows

Rather than requiring organizations to replace their existing sequencing infrastructure or adopt a new software platform, Genoxus offers an interpretation service that complements established sequencing and research workflows.

The service is designed for:

• Sequencing Companies: Extend existing sequencing services with additional variant interpretation and structured reporting capabilities.
• Research Laboratories: Investigate potentially relevant genetic findings in unresolved cases and research cohorts.
• Genetics Professionals: Access organized variant-level evidence to support further investigation and professional review.
• Healthcare Organizations: Explore additional interpretation capabilities within existing research and professional workflows.

GVA1.0 currently supports whole-exome sequencing (WES) data submitted in VCF format. Reports are typically delivered within five business days of VCF submission.

Genoxus welcomes opportunities to collaborate with sequencing providers, research institutions, and genomics organizations interested in evaluating its approach, conducting pilot analyses, and exploring potential partnerships.

Read the White Paper and Learn More:

Download White Paper [PDF]: From Genetic Variation to Disease Hypotheses: A Systematic Approach to Genomic Interpretation

About Genoxus

Genoxus is a genomics technology organization focused on transforming how genetic data is interpreted and utilized. Through both its for-profit and nonprofit initiatives, Genoxus builds scalable, cloud-native solutions and community-driven programs that empower researchers, clinicians, and individuals to unlock actionable insights from complex genomic data. The organization’s mission is to accelerate precision medicine by making high-quality genomic interpretation more accessible, efficient, and impactful worldwide.

Genoxus Press/Media Contact:
Email: annabelle@genoxuslabs.com
Website: https://genoxuslabs.com

Important notice: Genetic data exploration and research findings do not, by themselves, establish a medical diagnosis or determine an individual’s health needs. Wild Hippie Lab provides wellness education, not medical advice, diagnosis, or treatment. Individuals should consult qualified healthcare professionals before making medical decisions or changing supplements or treatments based on genetic information.